Illumina is projected to report Q2 2026 revenue of $1.12 billion and EPS of $1.23, as the current stock price of $128.45 seeks to close the gap toward the $152.00 analyst price target.
Investors are primarily focused on the Core Illumina operating margin as the company stabilizes its cost structure following the full divestiture of GRAIL.
Analysts are specifically looking for a rebound in NovaSeq X consumable pull-through, which serves as a leading indicator for recurring revenue growth. The market remains cautious regarding biopharma spending trends, making the company’s updated full-year 2026 guidance a critical catalyst for the stock.